Navigation Links
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
Date:5/14/2008


* Philip Beachy, Ph.D., Stanford University Institute for Stem Cell

Biology and Regenerative Medicine and HHMI, has pioneered the use of

synthetic small molecules and natural products to manipulate activities

of developmental and stem cell signaling pathways in vitro and in vivo.

* Sheng Ding, Ph.D., Scripps Research Institute, has worked on the

identification of small molecules and genes that control cell fate,

including cell reprogramming and differentiation. Dr. Ding's work has

important implications for the development of small molecule drugs that

can potentiate adult stem cells in vivo, and reprogram differentiated

cells to new functions.

* Randall Moon, Ph.D., University of Washington; Director, Institute for

Stem Cell and Regenerative Medicine; HHMI; and UW Department of

Pharmacology, has focused on illuminating the biological pathways that

control adult stem cells during the process of regeneration to develop

new therapeutic methods to activate regeneration.

* David Scadden, M.D., Professor, Harvard University; Co-Director and

Co-Founder, Harvard Stem Cell Institute; Director, Massachusetts

General Hospital Center for Regenerative Medicine, has broken new

ground in understanding how blood forming stem cells and other adult

stem cells are maintained in the adult body in specialized niches, and

in developing therapies that exploit this biology to modulate adult

stem cells in vivo.

* Leonard Zon, M.D., Harvard University; Director of the Stem Cell

Program, Children's Hospital of Boston; and HHMI, is a world expert on

the biology of adult blood forming stem cells and methods of enhancing

their function for cancer and regenerative medicine applications.

Formed in early 2007, Fate Therapeutics raised $15 million in its Series A fin
'/>"/>

SOURCE Fate Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
5. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
6. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
9. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
(Date:8/26/2014)... Diego, CA, and Bellingham, WA (PRWEB) August 26, ... and optical engineering, visions for next-generation wearable technology, ... 2015 among numerous highlights at this year’s brighter, ... the San Diego, California, Convention Center. More than ... last week attended conferences, courses, an exhibition, and ...
(Date:8/26/2014)... August 26, 2014 The 20 ambassadors ... ALS (YFALS) community issued the following statement on Facebook ... awareness and driving new funding specifically for ALS research: ... water and some ice would raise all this awareness ... our families, and on behalf of the entire ALS ...
(Date:8/26/2014)... been added to the growing case for graphene ... big thing in the high-tech world by the ... collaboration of researchers led by a scientist with ... National Laboratory (Berkeley Lab) has reported the first ... MX2 materials. The recorded charge transfer time clocked ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Competition for graphene 2
... Dec. 13, 2011  GenVec, Inc. (Nasdaq: GNVC ... create superior therapeutics and vaccines, today announced that Paul ... his plan to retire as President and Chief Executive ... a successor is named and the CEO transition is ...
... Tarsa Therapeutics today confirmed that it is planning ... Food and Drug Administration (FDA) in the second half ... calcitonin tablet for the treatment of postmenopausal osteoporosis. This follows ... the results from Tarsa,s Phase III ORACAL trial and ...
... - The Pharmabiotic Research Institute (PRI) brings ... probiotics research. It is a unique scientific and regulatory ... that, beyond their traditional food processing applications, probiotics can ... potential. This is why PRI uses the terminology "Pharmabiotics", ...
Cached Biology Technology:GenVec President and Chief Executive Officer Announces Retirement 2GenVec President and Chief Executive Officer Announces Retirement 3Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 2The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 4
(Date:8/27/2014)... into doubt the long-standing belief that a deficiency in ... plays a central role in depression. In the journal ... lacking the ability to make serotonin in their brains ... did not show depression-like symptoms. , Donald Kuhn ... Center and Wayne State University School of Medicine note ...
(Date:8/27/2014)... to be associated with outcomes after the repair ... the patient, mechanism of injury, nerve injured, injury ... technique, and repair materials. However, despite numerous studies ... injuries, there is no agreement regarding the independent ... relationship of the predictors has not been quantified. ...
(Date:8/27/2014)... North Carolina State University have found that century-old museum specimens ... common insect pest that can weaken and kill trees ... that scale insect populations increase on oak and maple trees ... pests may also increase with global warming," says Dr. Elsa ... of a paper on the work. , "More scale insects ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... human brain is not completed at birth. There is ... place in the human brain throughout life, probably for ... that brain structure is under considerable genetic influence [Peper ... into adulthood, involves changes in brain morphology that may ...
... , Mammography continues to be the method of ... because this technique is not as selective or specific ... results for every level of tissue density, alternatives are ... of near-infrared (NIR) light instead of X-rays, is a ...
... MANHATTAN, KAN. -- An award-winning Kansas State University chemistry ... recognizing him for work on microfluidic devices. Chris ... Masao Horiba Award for "Rapid Analysis of Individual T-Lymphocyte ... Wednesday, Oct. 17, during a special ceremony at Kyoto ...
Cached Biology News:Genetic contributions to human brain morphology and intelligence 2Genetic contributions to human brain morphology and intelligence 3Genetic contributions to human brain morphology and intelligence 4Genetic contributions to human brain morphology and intelligence 5Contrast agent trials in swine 2K-State chemistry professor to receive Masao Horiba award 2
... Mount is formulated for covering tissue sections and cell preparations ... end products. , ... Application: ... or AEC that require an aqueous mounting medium, or those ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Solution, pH 9 (x 10) This ... intended for heat-induced target retrieval prior to ... use on formalin-fixed, paraffin-embedded tissue sections mounted ... citrate buffer, pH 6, the use of ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Biology Products: